Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma Christine Cordova, MD, Andrew S. Chi,

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Recurrent cerebral embolism secondary to esophageal and atrial foreign body complicated by infective endocarditis Hui Liang, MD, Ziqi Xu, MD, Qiang Feng,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Volume 50, Issue 1, Pages (January 2014)

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report Kazutaka Fujita, MD, Yuko.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Leptomeningeal Infiltration, the Hallmark of Neurosarcoidosis

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions Nathan D. Gay, MD, Ying Wang, MD, Carol Beadling, PhD, Andrea Warrick,

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient Biagio Ricciuti,

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Complicated Necrotizing Otitis Externa Progressing to Coalescent Mastoiditis and Temporal Lobe Abscess Talha Demirci, MD, Sharon O'Brien, MD The American.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

Jessica J. Lin, MD, Elizabeth Kennedy, BA, Lecia V

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Presentation of Garcin Syndrome due to Lung Cancer

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Complete and Durable Response of Choroid Metastasis from Non-small Cell Lung Cancer with Systemic Bevacizumab and Chemotherapy Ben George, MD, William.

David Garfield, MD Journal of Thoracic Oncology

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing.

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report Katarzyna Dziadziuszko, MD, Edyta Szurowska, MD, PhD, Joanna.

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma Christine Cordova, MD, Andrew S. Chi, MD, PhD, Abraham Chachoua, MD Journal of Thoracic Oncology Volume 12, Issue 11, Pages e188-e190 (November 2017) DOI: 10.1016/j.jtho.2017.07.029 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Brain magnetic resonance imaging scans showing regression of focal leptomeningeal disease. (A) Axial postgadolinium T1-weighted image notable for leptomeningeal enhancement along cerebral sulci of the right temporal lobe (red arrow). (B) Postgadolinium T1-weighted magnetic resonance imaging scan after 2 months of dose-escalated osimertinib showing partial resolution of leptomeningeal enhancement (red arrow). Journal of Thoracic Oncology 2017 12, e188-e190DOI: (10.1016/j.jtho.2017.07.029) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Brain magnetic resonance imaging (MRI) scans showing regression of leptomeningeal disease along cranial nerves. (A) Axial postgadolinium T1-weighted image notable for thickening and leptomeningeal enhancement along the right trigeminal nerve (red arrow). (B) Postgadolinium T1-weighted MRI scan after 2 months of dose-escalated osimertinib showing decreased thickness and partial resolution of leptomeningeal enhancement along the right trigeminal nerve (red arrow). (C) Axial postgadolinium T1-weighted image notable for thickening and leptomeningeal enhancement coating of the seventh and eighth cranial nerves bilaterally in the internal auditory canals (red arrows) (D) Postgadolinium T1-weighted MRI performed after 2 months of dose-escalated osimertinib showing decreased thickness and partial resolution of leptomeningeal enhancement along the bilateral seventh/eighth nerve complexes (red arrow). Journal of Thoracic Oncology 2017 12, e188-e190DOI: (10.1016/j.jtho.2017.07.029) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions